

Our Ref: 189  
February 2024

## Re: Your request made under the Freedom of Information Act 2000

Wilmington Healthcare are researching the treatment of myeloproliferative neoplasms. We would greatly appreciate if you could answer the following questions:

Q1. Please provide the total number of patients treated in the last 6 months for:

- Polycythaemia Vera (ICD10 code D45) **86**
- Myelofibrosis (ICD10 code D47.4) **9**
- Myelofibrosis (ICD10 code D47.4) patients aged 65 and older **9**

Q2. How many patients were treated in the past 6 months (for any disease) with:

- Ruxolitinib **23**
- Fedratinib **1**
- Momelotinib **0**

Q3. How many patients were treated in the past 6 months for Myelofibrosis (ICD10 code D47.4) with:

- Ruxolitinib
- Fedratinib
- Momelotinib

**Our pharmacy system doesn't store diagnosis data, so we're unable to determine this against the prescribed treatment. To ascertain this data, the Trust would need to perform an audit of each individual patient record, which wouldn't be achievable within the s.12 timescale of the Freedom of Information Act 2000.**

Q4. How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years? **19**

- Of these patients, how many were treated in the past 6 months with Hydroxycarbamide?
- Of these patients, how many were treated in the past 6 months with Interferon therapy?
- Of these patients, how many have received no active treatment in the past 6 months?

**Our pharmacy system doesn't store diagnosis data, so we're unable to determine this against the prescribed treatment. To ascertain this data, the Trust would need to perform an audit of each individual patient record, which wouldn't be achievable within the s.12 timescale of the Freedom of Information Act 2000.**

Q5. Does your trust participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part.

Our Ref: 189  
February 2024

No, we are not currently running any clinical trials for the treatment of myelofibrosis.